Peptide reference

Kisspeptin

Metastin ·KISS1 ·Kisspeptin-54 ·Kisspeptin-10 ·KP-54 ·KP-10

Structural class
Endogenous neuropeptide; KISS1 gene product (54-, 14-, 13-, and 10-residue C-terminal fragments)
Last updated
2026-05-03

What cited sources report about kisspeptin

Kisspeptin is an endogenous neuropeptide encoded by the KISS1 gene, secreted primarily by hypothalamic neurons, and signaling through the GPR54 (KISS1R) receptor on gonadotropin-releasing hormone neurons. Synthetic fragments — particularly kisspeptin-54 (KP-54) and kisspeptin-10 (KP-10) — have been investigated in human reproductive endocrinology. As of the cited literature, kisspeptin has no FDA-approved indication and no marketing authorization in any major jurisdiction. The summaries below report what individual cited sources state; this page does not assert claims beyond what those sources report.

Velmurugan et al. (2025) — Current Medicinal Chemistry

A systematic review that screened the indexed literature and identified 29 interventional clinical trials of kisspeptin across amenorrhea, puberty, fertility, lactation, and HPO-axis probing protocols. The authors documented the GPR54 mechanism, summarized adverse-event profiles as generally mild, and noted that no completed phase-3 confirmatory program supports a marketing application in any jurisdiction.

Kisspeptin can be viewed as a multipurpose drug with considerably fewer side effects due to its effects simulating normal physiological processes in our body.

PMID:38265397 ↗

Abbara et al. (2015) — Journal of Clinical Endocrinology and Metabolism

A dose-finding phase-2 trial conducted by the Imperial College London group in 60 women at high risk of ovarian hyperstimulation syndrome during IVF. The investigators administered single subcutaneous doses of kisspeptin-54 (3.2-12.8 nmol/kg) 36 hours before oocyte retrieval and reported oocyte maturation in 95% of women, no cases of moderate-to-critical OHSS, and a clinical pregnancy rate of 53% per transfer.

Kisspeptin-54 is a promising approach to effectively and safely trigger oocyte maturation in women undergoing IVF treatment at high risk of developing OHSS.

PMID:26192876 ↗

PubChem CID 25240297 — National Center for Biotechnology Information

The PubChem compound record for Kisspeptin-10 lists the molecular formula C63H83N17O14 and identifies the entry as the C-terminal decapeptide of the KISS1 gene product, also known as metastin 45-54. The record aggregates synonyms (KP-10, metastin 45-54) and links to the underlying KISS1/metastin literature.

PubChem CID 25240297 ↗

Coverage notes

Most published human data on kisspeptin originates from a small number of academic groups (notably Imperial College London/Hammersmith) and is dominated by physiology and IVF-trigger protocols using kisspeptin-54. No FDA-approved kisspeptin product exists, and the systematic review cited above did not identify a registered phase-3 program intended to support a marketing application. Endogenous KISS1 biology and oncology applications (under the alternative name “metastin”) are extensively published but lie outside the regulatory-status focus of this page.